Executive Summary Information
|Mechanisms||Toxicity is ascribed to the antifolate activity of the parent compound.|
|Comments||This compound was selected because the fibrotic activity is induced by a relatively limited biochemical activity without accompanying chemical reactivity.|
|Feedback Contact||Gold Compound Working Group (GCWG)|
|Target||Dihydrofolate reductase (DHFR) inhibition|
FDA and Label Information
The following link will display all of the currently approved FDA drug products on the market. The web page will contain a table listing all current products by their respective Tradenames and primary active ingredients. The list is navigable by simply clicking on the product of interest, which will in turn list all of the NDA's and ANDA's associated with that product. From here users can click on a specific NDA or ANDA and see documents that have been submitted for the product that the FDA has made available via their website. The types of documents include approval history, letters, reviews and labels.
FDA Approved Products
This next url will perform a search in the FDA's system for all labels for products that contain Methotrexate as an active ingredient.
FDA Label Search
Since every unique drug product receives a separate label, we have included a link to another resource for a specific Acetaminophen product (Methotrexate sodium tables - by Rebel Distributors Corp.) which displays the drug label information.
The following resource link will perform a PubMed query for the terms " Methotrexate " and "liver toxicity".
The following resource link will perform a PubMed query for the terms " Methotrexate " and "cardio toxicity".
The recommended source is Sigma Aldrich, product number M8407.
|Mol Weight||Methotrexate hydrate 454.44 (anhydrous basis)|
|Comment||The product is the L-Enantiomer of Methotrexate. Product defined suitable for cell culture|
|Storage||Store at -20 °C. Keep in a dry place|